- Qualigen Therapeutics (OTC: QBAK) is implementing a 3-for-1 forward stock split, increasing the number of shares without immediately altering the total investment value.
- Cleared by the Financial Industry Regulatory Authority (FINRA), the split’s ex-date is set for April 28, 2026, with new share structure trading commencing on April 29, 2026, on the OTC Markets.
- The company’s stock symbol will temporarily change to QBAKD for 20 business days post-split before reverting to QBAK, a standard market notification practice.
Qualigen Therapeutics (OTC: QBAK) is a therapeutics company that trades on the OTC exchange. The company focuses on developing treatments for various medical conditions. It currently has a market capitalization of approximately $64.43 million, which is the total value of all its shares in the market.
Qualigen Therapeutics has announced a 3-for-1 forward stock split. A stock split increases the number of a company’s shares to make them more affordable for investors. For every one share an investor owns, they will receive three shares after the split, but the total value of their investment remains the same initially.
As highlighted by GlobeNewswire, the Financial Industry Regulatory Authority (FINRA) has cleared the split. The change is set to be reflected in shareholder accounts on the ex-date of April 28, 2026. Trading with the new share structure will begin on the OTC Markets on April 29, 2026.
Following the split, Qualigen Therapeutics’ stock symbol will temporarily change to QBAKD. This change will last for 20 business days to notify the market of the recent corporate action. Afterward, the symbol will revert to QBAK. This is a standard process for stocks that undergo such changes.
Currently, QBAK is trading at $11.40 per share. The stock’s price has moved between a low of $1.83 and a high of $11.40 over the past 52 weeks. The trading volume for the day is low at 341 shares, indicating limited trading activity.
